Hyloris Pharmaceuticals (HYL) Investor Presentation summary

Company overview

• Focuses on reformulating and repurposing existing drugs to address unmet medical needs, aiming for a global portfolio of 30 cardiovascular and other value-added assets.

• Based in Liège, Belgium, founded in 2012, and listed on Euronext Brussels; co-founders hold 41% of shares.

• Executive team has deep expertise in regulatory affairs, market access, and capital markets, with involvement in over 80 approved drugs and 300+ licensing transactions.

• Employs over 40 people from 11 nationalities, emphasizing a track record of shareholder value creation.

Business model and strategy

• Targets value-added medicines by reformulating or repurposing off-patent compounds, focusing on efficacy, safety, compliance, and convenience.

• Pursues faster innovation cycles, with an average of ≤7 years to market and ≤€7 million cost per product.

• Selects product candidates based on clear scientific rationale, technical feasibility, and regulatory pathways, aiming for fast market adoption and maximized ROI.

• Maintains a diversified portfolio with strong patent protection and addresses clear unmet needs in healthcare.

Product portfolio

• Cardiovascular pipeline includes Sotalol IV, Aspirin IV, Milrinone ER, Dofetilide IV, and others, with several products partnered for commercialization.

• Broader portfolio covers pain management, oncology, infectious diseases, and rare conditions, with products like Maxigesic IV, Podofilox Gel, Alenura, and others.

• Recent pipeline additions target conditions such as Burning Mouth Syndrome (HY-090), Vulvar Lichen Sclerosus (HY-091), and Equine Gastric Ulcer Syndrome (HY-095), all in partnership with AFT Pharmaceuticals.

• Maxigesic IV, Sotalol IV, and Podofilox Gel are commercialized, with Maxigesic IV launched in the US in early 2024 and approved in over 50 countries.